Search

Your search keyword '"Azmi, Farhana"' showing total 9 results
Start Over Author "Azmi, Farhana"
9 results on '"Azmi, Farhana"'

3. Developing Renal Clearable Nanoparticles for the Treatment of Renal Cell Carcinoma

Author

Azmi, Farhana

Subjects
Nanomedicine, treatment, Carbon Dots, Kidney, Cancer
Abstract

Renal Cell Carcinoma (RCC) is the most common form of kidney cancer and has proven itself to be difficult to treat with conventional chemotherapy and radiotherapy. Nanoparticles (NPs), however, have been shown to significantly improve the efficacy of chemotherapy for RCC in recent years. A primary issue with using NPs is the safety concerns and potential side effects such as their permanent accumulation in major organs. To address this issue, the focus of my PhD study is the synthesis of novel non-toxic NPs that can be cleared by the kidneys or biocompatible/biodegradable NPs that can be used to deliver drugs/inhibitors to combat RCC. In this study, four type of renal clearable carbon dots and two types of biocompatible NPs have been developed. Among all these NPs, renal clearable NP called Sucrose Carbon Dots (Suc CDs) were created to carry hydrophilic drugs and Polymeric Micelles (P.M) were employed to carry hydrophobic drugs. Suc CDs ware developed with size

Published
2022

4. Conventional Type 1 Dendritic Cells (cDC1) in Human Kidney Diseases: Clinico-Pathological Correlations

Author

Chen, Titi, primary, Cao, Qi, additional, Wang, Ruifeng, additional, Zheng, Guoping, additional, Azmi, Farhana, additional, Wang, Jeffery, additional, Lee, Vincent W., additional, Wang, Yuan Min, additional, Yu, Hong, additional, Patel, Manish, additional, P’ng, Chow Heok, additional, Alexander, Stephen I., additional, Rogers, Natasha M., additional, Wang, Yiping, additional, and Harris, David C. H., additional

Published
2021
Full Text
View/download PDF

6. Regulatory innate lymphoid cells suppress innate immunity and reduce renal ischemia/reperfusion injury

Author

Cao, Qi, primary, Wang, Ruifeng, additional, Wang, Yiping, additional, Niu, Zhiguo, additional, Chen, Titi, additional, Wang, Chengshi, additional, Jin, Li, additional, Huang, Qingsong, additional, Li, Qing, additional, Wang, Xin Maggie, additional, Azmi, Farhana, additional, Lee, Vincent W.S., additional, Wang, Yuan Min, additional, Zheng, Guoping, additional, Alexander, Stephen I., additional, and Harris, David C.H., additional

Published
2020
Full Text
View/download PDF

8. The potential role of Ets-1 and miR-326 in CD19+B cells in the pathogenesis of patients with systemic lupus erythematosus.

Author

Jin, Li, Fang, Xuan, Dai, Chao, Xiang, Nan, Tao, Jinhui, Sun, Xiaoge, Azmi, Farhana, Cao, Qi, Li, Xiaomei, Wang, Yiping, and Li, Xiangpei

Subjects
SYSTEMIC lupus erythematosus, B cell differentiation, CELLS, TRANSCRIPTION factors
Abstract

Objectives: The aim of this study was to investigate the B cell-associated transcription factors, Ets-1 and microRNA, miR-326 in systemic lupus erythematosus (SLE) patients, and their correlation with the pathogenesis of SLE.Method: A total of 44 SLE patients and 20 healthy controls were enrolled in this research, all patients fulfilled the American College of Rheumatology classification criteria for SLE. The mRNA expression of Ets-1 and miR-326 in CD19+B cells from SLE patients were examined by qRT-PCR. The percentages of CD19+CD138+plasma cells were analyzed by Flow cytometry.Results: We found decreased expression of Ets-1 mRNA in SLE patients compared with the healthy controls ([0.228 (0.145, 0.507)] vs [0.583 (0.452, 0.763)], p = 0.001),while increased expression of miR-326 mRNA in CD19+B cells SLE patients compared with the healthy controls([1.092 (0.457, 2.855)] vs [0.685 (0.274, 0.819)], p = 0.008). The percentage of CD19+CD138+plasma cells in SLE patients was higher than that of healthy controls (0.55 ± 0.21% vs 0.36 ± 0.21%, p = 0.002). Moreover, a negative correlation between expression of Ets-1 mRNA and miR-326 mRNA in CD19+B cells was detected (r = − 0.334, p = 0.027). A significant association between the occurrences of CD19+CD138+plasma cells and the levels of Ets-1 mRNA and miR-326 mRNA was observed (r = − 0.417, p = 0.005 and r = 0.482, p = 0.001, respectively).Conclusions: Our results suggest that miR-326 might promote B cells differentiation by targeting Ets-1, a negative regulator of B cells differentiation and therefore participate in the pathogenesis of SLE. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

9. The potential role of Ets-1 and miR-326 in CD19 + B cells in the pathogenesis of patients with systemic lupus erythematosus.

Author

Jin L, Fang X, Dai C, Xiang N, Tao J, Sun X, Azmi F, Cao Q, Li X, Wang Y, and Li X

Subjects
Adult, Cell Differentiation, Female, Flow Cytometry, Humans, Male, Antigens, CD19 metabolism, B-Lymphocytes metabolism, Lupus Erythematosus, Systemic metabolism, MicroRNAs metabolism, Proto-Oncogene Protein c-ets-1 metabolism
Abstract

Objectives: The aim of this study was to investigate the B cell-associated transcription factors, Ets-1 and microRNA, miR-326 in systemic lupus erythematosus (SLE) patients, and their correlation with the pathogenesis of SLE., Method: A total of 44 SLE patients and 20 healthy controls were enrolled in this research, all patients fulfilled the American College of Rheumatology classification criteria for SLE. The mRNA expression of Ets-1 and miR-326 in CD19 + B cells from SLE patients were examined by qRT-PCR. The percentages of CD19 + CD138 + plasma cells were analyzed by Flow cytometry., Results: We found decreased expression of Ets-1 mRNA in SLE patients compared with the healthy controls ([0.228 (0.145, 0.507)] vs [0.583 (0.452, 0.763)], p = 0.001),while increased expression of miR-326 mRNA in CD19 + B cells SLE patients compared with the healthy controls([1.092 (0.457, 2.855)] vs [0.685 (0.274, 0.819)], p = 0.008). The percentage of CD19 + CD138 + plasma cells in SLE patients was higher than that of healthy controls (0.55 ± 0.21% vs 0.36 ± 0.21%, p = 0.002). Moreover, a negative correlation between expression of Ets-1 mRNA and miR-326 mRNA in CD19 + B cells was detected (r = - 0.334, p = 0.027). A significant association between the occurrences of CD19 + CD138 + plasma cells and the levels of Ets-1 mRNA and miR-326 mRNA was observed (r = - 0.417, p = 0.005 and r = 0.482, p = 0.001, respectively)., Conclusions: Our results suggest that miR-326 might promote B cells differentiation by targeting Ets-1, a negative regulator of B cells differentiation and therefore participate in the pathogenesis of SLE.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results